title: TA-CD. Xenova.
abstract: TA-CD (formerly IPC-1010), a cocaine conjugate that stimulates the production of antibodies against cocaine, is under development by Xenova (formerly Cantab) for the potential treatment of cocaine dependence [176912], [414867], [449997]. The vaccine was originally discovered at Stanford University and exclusively licensed to ImmuLogic Pharmaceuticals as IPC-1010 [176908]. It was renamed TA-CD when ownership was transferred to Cantab [463510], [463511]. By April 2002, a second phase IIa dose escalation trial was underway [445298], which was ongoing in September 2002 [463866].
authors.affiliation: Department of Biological Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK. moore11@globalnet.co.uk
authors.forename: Christine E
authors.initials: CE
authors.lastname: Heading